Cyclin D2 Regulation Of Islet Growth

Information

  • Research Project
  • 6861567
  • ApplicationId
    6861567
  • Core Project Number
    K08DK064101
  • Full Project Number
    7K08DK064101-02
  • Serial Number
    64101
  • FOA Number
    PA-00-03
  • Sub Project Id
  • Project Start Date
    1/1/2004 - 20 years ago
  • Project End Date
    9/29/2008 - 16 years ago
  • Program Officer Name
    HYDE, JAMES F
  • Budget Start Date
    1/1/2004 - 20 years ago
  • Budget End Date
    9/29/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    2
  • Suffix
  • Award Notice Date
    2/27/2004 - 20 years ago

Cyclin D2 Regulation Of Islet Growth

DESCRIPTION (provided by applicant): My goal as a physician-scientist is to improve the lives of children through research on the pathophysiology of diabetes mellitus. To this end I have spent the past several years training in the laboratory of Dr Morris White investigating the etiology of beta-cell dysfunction in diabetes. This proposal will allow me to further train in cell biology and physiology as I transition to a career as an independently funded investigator in the Joslin Diabetes Center. Little is known about the regulation of beta-cell proliferation, although the insulin-like growth factors (IGFs), other growth factors, and the pancreatic transcription factor Pdx1 may play a role. Insulin Receptor Substrate (IRS)-2 related pathways are essential for beta-cell survival: Irs2 knockout (-/-) mice develop beta-cell failure and insulin resistance resulting in death from diabetes. I have previously shown that Irs2 signaling alters levels of Pdx1, a pancreatic transcription factor that promotes beta-cell mass and function. I also found that Pdx1 overexpression can stimulate beta-cell proliferation in mice, as measured by BrdU incorporation into beta-cells. In most tissues mitogenic stimuli increase gene expression of G1 cyclin D-type cyclins, which partner with cyclin dependent kinase (cdk)-4 or -6 to promote cell growth. Remarkably, cdk4-/- mice develop diabetes from inadequate beta-cell growth. From these findings I suspected that one of the D-type cyclins might be an important partner of cdk4 in islet expansion. Supporting this notion I have recently found that cyclin D2-/- mice develop diabetes with impaired beta-cell growth. Further experiments suggest that Pdx1 could regulate beta-cell proliferation by directly binding to the cyclin D2 promoter. This proposal will test the hypothesis that cyclin D2 is essential for normal islet growth and that Pdx1 regulates beta-cell proliferation by regulating cyclin D2 activity by examining the following specific aims: 1. To test if cyclin D2 is an essential regulator of islet growth. 2. To test if Pdx1 influences beta-cell proliferation by regulating cyclin D2.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    K08
  • Administering IC
    DK
  • Application Type
    7
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    102511
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:102511\
  • Funding Mechanism
  • Study Section
    DDK
  • Study Section Name
    Diabetes and Digestive and Kidney Diseases Special Grants Review Committee
  • Organization Name
    CHILDREN'S HOSPITAL OF PHILADELPHIA
  • Organization Department
  • Organization DUNS
    073757627
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191044318
  • Organization District
    UNITED STATES